Oncolytic Viruses in Cancer Therapy

Overview

Journal Cancer Lett

Specialty Oncology

Date 2007 Mar 27

PMID 17383089

Citations 141

Authors

Markus J V Vaha-Koskela

Jari E Heikkila

Ari E Hinkkanen

Affiliations

Soon will be listed here.

Abstract

Oncolytic virotherapy is a promising form of gene therapy for cancer, employing nature's own agents to find and destroy malignant cells. The purpose of this review is to provide an introduction to this very topical field of research and to point out some of the current observations, insights and ideas circulating in the literature. We have strived to acknowledge as many different oncolytic viruses as possible to give a broader picture of targeting cancer using viruses. Some of the newest additions to the panel of oncolytic viruses include the avian adenovirus, foamy virus, myxoma virus, yaba-like disease virus, echovirus type 1, bovine herpesvirus 4, Saimiri virus, feline panleukopenia virus, Sendai virus and the non-human coronaviruses. Although promising, virotherapy still faces many obstacles that need to be addressed, including the emergence of virus-resistant tumor cells.

Citing Articles

Comparison of differences in immune cells and immune microenvironment among different kinds of oncolytic virus treatments.

Wu X, Fang S Front Immunol. 2024; 15:1494887.

PMID: 39588373 PMC: 11586384. DOI: 10.3389/fimmu.2024.1494887.

Progression of oncolytic virus in liver cancer treatment.

Hua X, Xuan S, Tang Y, You S, Zhao S, Qiu Y Front Oncol. 2024; 14:1446085.

PMID: 39391253 PMC: 11464341. DOI: 10.3389/fonc.2024.1446085.

Oncolytic Tanapoxvirus Variants Expressing mIL-2 and mCCL-2 Regress Human Pancreatic Cancer Xenografts in Nude Mice.

Haller S, Essani K Biomedicines. 2024; 12(8).

PMID: 39200298 PMC: 11351728. DOI: 10.3390/biomedicines12081834.

Enhancement of Therapeutic Potential of Oncolytic Virus with Homologous Tumor Cell Membranes for Pancreatic Cancer.

Chen W, Liu H, Chen Y, Gao M IET Nanobiotechnol. 2024; 2024:9970665.

PMID: 38863971 PMC: 11095071. DOI: 10.1049/2024/9970665.

Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma.

Meng L, Collier K, Wang P, Li Z, Monk P, Mortazavi A Cells. 2024; 13(1).

PMID: 38201238 PMC: 10777977. DOI: 10.3390/cells13010034.

References

Vaha-Koskela M, Kallio J, Jansson L, Heikkila J, Zakhartchenko V, Kallajoki M . Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice. Cancer Res. 2006; 66(14):7185-94. DOI: 10.1158/0008-5472.CAN-05-2214. View

Smyth M, SYMONDS A, Brazinova S, Martin J . Bovine enterovirus as an oncolytic virus: foetal calf serum facilitates its infection of human cells. Int J Mol Med. 2002; 10(1):49-53. DOI: 10.3892/ijmm.10.1.49. View

Ram Z, Culver K, Oshiro E, Viola J, DeVroom H, Otto E . Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med. 1997; 3(12):1354-61. DOI: 10.1038/nm1297-1354. View

Frenkel N, Borenstein R . Characterization of the lymphotropic amplicons-6 and tamplicon-7 vectors derived from HHV-6 and HHV-7. Curr Gene Ther. 2006; 6(3):399-420. DOI: 10.2174/156652306777592036. View

Pokorna D, cerovska N, Smahel M, Moravec T, Ludvikova V, Mackova J . DNA vaccines based on chimeric potyvirus-like particles carrying HPV16 E7 peptide (aa 44-60). Oncol Rep. 2005; 14(4):1045-53. View

Nakamori M, Fu X, Meng F, Jin A, Tao L, Bast Jr R . Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms. Clin Cancer Res. 2003; 9(7):2727-33. View

Recchia A, Bonini C, Magnani Z, Urbinati F, Sartori D, Muraro S . Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc Natl Acad Sci U S A. 2006; 103(5):1457-62. PMC: 1360534. DOI: 10.1073/pnas.0507496103. View

McCart J, Ward J, Lee J, Hu Y, Alexander H, Libutti S . Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 2001; 61(24):8751-7. View

Kanerva A, Zinn K, Peng K, Ranki T, Kangasniemi L, Chaudhuri T . Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus. Gene Ther. 2004; 12(1):87-94. DOI: 10.1038/sj.gt.3302387. View

10.

Sinkovics J, Horvath J . Evidence accumulating in support of cancer vaccines combined with chemotherapy: a pragmatic review of past and present efforts. Int J Oncol. 2006; 29(4):765-77. View

11.

Kasuya H, Mizuno M, Yoshida J, Nishiyama Y, Nomoto S, Nakao A . Combined effects of adeno-associated virus vector and a herpes simplex virus mutant as neoplastic therapy. J Surg Oncol. 2000; 74(3):214-8. DOI: 10.1002/1096-9098(200007)74:3<214::aid-jso12>3.0.co;2-y. View

12.

Liu B, Robinson M, Han Z, Branston R, English C, Reay P . ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003; 10(4):292-303. DOI: 10.1038/sj.gt.3301885. View

13.

Nakao A, Kimata H, Imai T, Kikumori T, Teshigahara O, Nagasaka T . Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer. Ann Oncol. 2004; 15(6):988-9. DOI: 10.1093/annonc/mdh225. View

14.

Wagner S, Csatary C, Gosztonyi G, Koch H, Hartmann C, Peters O . Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid. APMIS. 2006; 114(10):731-43. DOI: 10.1111/j.1600-0463.2006.apm_516.x. View

15.

Todo T, Martuza R, Rabkin S, Johnson P . Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A. 2001; 98(11):6396-401. PMC: 33479. DOI: 10.1073/pnas.101136398. View

16.

Wurdinger T, Verheije M, Raaben M, Bosch B, de Haan C, van Beusechem V . Targeting non-human coronaviruses to human cancer cells using a bispecific single-chain antibody. Gene Ther. 2005; 12(18):1394-404. PMC: 7091791. DOI: 10.1038/sj.gt.3302535. View

17.

Sarinella F, Calistri A, Sette P, Palu G, Parolin C . Oncolysis of pancreatic tumour cells by a gamma34.5-deleted HSV-1 does not rely upon Ras-activation, but on the PI 3-kinase pathway. Gene Ther. 2006; 13(14):1080-7. DOI: 10.1038/sj.gt.3302770. View

18.

Shinoura N, Yoshida Y, Asai A, Kirino T, Hamada H . Adenovirus-mediated transfer of p53 and Fas ligand drastically enhances apoptosis in gliomas. Cancer Gene Ther. 2000; 7(5):732-8. DOI: 10.1038/sj.cgt.7700160. View

19.

Ochiai H, Campbell S, Archer G, Chewning T, Dragunsky E, Ivanov A . Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus. Clin Cancer Res. 2006; 12(4):1349-54. DOI: 10.1158/1078-0432.CCR-05-1595. View

20.

Minchinton A, Tannock I . Drug penetration in solid tumours. Nat Rev Cancer. 2006; 6(8):583-92. DOI: 10.1038/nrc1893. View